<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="56871">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01719133</url>
  </required_header>
  <id_info>
    <org_study_id>AN002</org_study_id>
    <nct_id>NCT01719133</nct_id>
  </id_info>
  <brief_title>Skin Prick Tests With AllerT in Subjects Allergic to Birch Pollen</brief_title>
  <official_title>Détermination de la réactivité cutanée de Volontaires Allergiques au Pollen de Bouleau Contre Des Peptides dérivés de Bet v 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anergis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anergis</source>
  <oversight_info>
    <authority>Switzerland: Swissmedic</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of skin reactivity by skin prick tests to synthetic peptides derived from the
      major birch allergen bet v 1, in subjects allergic to birch pollen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study tested - all by skin tests - in the same group of 20 trial subjects, one positive
      control (histamine solution), one negative control (placebo saline) and five experimental
      peptides called T1, T2, T3, T4 and T5. Results of the skin prick tests were scored as
      negative (no reaction) or positive (wheal diameter &gt; 4 mm with erythema)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening</study_design>
  <primary_outcome>
    <measure>skin prick test reactivity</measure>
    <time_frame>15 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>All subjects</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>placebo histamine T1 T2 T3 T4 T5 T1-T2-T3 T4-T5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>saline solution</description>
    <arm_group_label>All subjects</arm_group_label>
    <other_name>saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Histamine</intervention_name>
    <description>positive control</description>
    <arm_group_label>All subjects</arm_group_label>
    <other_name>Histamine solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AllerT1</intervention_name>
    <description>synthetic peptide T1</description>
    <arm_group_label>All subjects</arm_group_label>
    <other_name>AllerT1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AllerT2</intervention_name>
    <description>synthetic peptide T2</description>
    <arm_group_label>All subjects</arm_group_label>
    <other_name>AllerT2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AllerT3</intervention_name>
    <description>synthetic peptide T3</description>
    <arm_group_label>All subjects</arm_group_label>
    <other_name>AllerT3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AllerT4</intervention_name>
    <description>synthetic peptide T4</description>
    <arm_group_label>All subjects</arm_group_label>
    <other_name>AllerT4</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AllerT5</intervention_name>
    <description>synthetic peptide T5</description>
    <arm_group_label>All subjects</arm_group_label>
    <other_name>AllerT5</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mix of AllerT1-T2-T3</intervention_name>
    <description>mix of peptides T1, T2 and T3</description>
    <arm_group_label>All subjects</arm_group_label>
    <other_name>AllerT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mix of AllerT4-T5</intervention_name>
    <description>mix T4-T5</description>
    <arm_group_label>All subjects</arm_group_label>
    <other_name>mix T4-T5</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  history of allergy symptoms during previous birch pollen season

          -  positive skin prick test to birch pollen extract

        Exclusion Criteria:

          -  pregnancy

          -  uncontrolled asthma

          -  other significant clinical conditions or immune disorders

          -  subjects taking antihistamines or drugs with antihistamine activity
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francois Spertini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire Vaudois</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>October 31, 2012</lastchanged_date>
  <firstreceived_date>October 26, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>allergy</keyword>
  <keyword>birch</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rhinitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Histamine</mesh_term>
    <mesh_term>Histamine phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
